Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 8/20 | 0.67 |
| ▸ | MAOB | P27338 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | AGXT | P21549 | 2/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6292403 | 1.00 | APP (0.67) | APPMAOBNPC1POLBRAB9A | |
| SCHEMBL20000873 | 0.89 | APP (0.80) | APPMAOBNPC1POLBRAB9A | |
| SCHEMBL8599573 | 0.84 | RXRA (0.59) | APPMAOBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL466371 | 0.84 | MAOB (0.59) | APPMAOBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18475585 | 0.82 | APP (0.69) | APPMAOBNPC1POLBRAB9A | |
| SCHEMBL13977985 | 0.82 | APP (0.69) | APPMAOBNPC1POLBRAB9A | |
| SCHEMBL553770 | 0.82 | APP (0.69) | APPMAOBNPC1POLBRAB9A | |
| SCHEMBL171857 | 0.82 | APP (0.69) | APPMAOBNPC1POLBRAB9A | |
| SCHEMBL13952163 | 0.82 | APP (0.69) | APPMAOBNPC1POLBRAB9A | |
| SCHEMBL13424151 | 0.82 | APP (0.69) | APPMAOBNPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0998946-A1 | Non-porphyrin compound for use as a diagnosticum and/or pharmaceutical | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2000-05-10 | — | — | EP | claimed |
| WO-2000009169-A1 | NON-PORPHYRIN COMPOUND FOR USE AS A DIAGNOSTICUM AND/OR PHARMACEUTICAL | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2000-02-24 | — | — | WO | claimed |
| US-7081472-B2 | Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them | K. U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2006-07-25 | — | — | US | disclosed |
| US-20040053911-A1 | Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2004-03-18 | — | — | US | disclosed |
| EP-1343758-A1 | SUBSTITUTED BIS-INDOLE DERIVATIVES USEFUL AS CONTRAST AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES FOR PRODUCING THEM | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002038546-A1 | SUBSTITUTED BIS-INDOLE DERIVATIVES USEFUL AS CONTRAST AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES FOR PRODUCING THEM | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053911-A1 | Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them | IDO1, IDO2, CNR1 | APP 3221/4885MAOB 59/4885NPC1 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.